Business news, market intelligence, and global industry analysis.
The Latest

Lupin launches schizophrenia drug Invega generic in US

byPallavi Madhiraju
October 21, 2022
Total
0
Shares
0
0
0

Indian pharma company Lupin Limited has launched Paliperidone Extended-Release Tablets, 1.5 mg, 3 mg, 6 mg, and 9 mg in the US.

The product is the generic version of Invega Extended-Release Tablets, 1.5 mg, 3 mg, 6 mg, and 9 mg, of Janssen Research and Development.

Invega (paliperidone), which is an atypical antipsychotic, which has approval in the US for the schizophrenia treatment in adults. It is also approved as a monotherapy for the treatment of schizoaffective disorder and as an adjunct for mood stabilizers and/or antidepressant therapy.

As per data from IQVIA MAT August 2022, Paliperidone Extended-Release Tablets had projected annual sales of $112 million in the US.

Discover more from Business-News-Today.com

Subscribe to get the latest posts sent to your email.

See also  Indian government approves use of Moderna’s Covid-19 Vaccine Moderna
Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Aptorum to develop drugs for treatment of obesity and neuroblastoma

Aptorum Group said that it will undertake the development of CLS-1 microbiome drug candidate and certain repurposed drug candidates for the treatment of obesity and neuroblastoma, respectively. Based in Hong Kong, Aptorum Group is a pharma company focused on the development of new drugs to treat unmet medical needs. The company said that its wholly-owned subsidiary […]

The post Aptorum to develop drugs for treatment of obesity and neuroblastoma appeared first on PharmaNewsDaily.com.

bypharmanewsdaily